Clinical Trials

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT06406465 2026-03-18

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

60 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

Advanced Lung Neuroendocrine Tumor

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

150 enrolled

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT05988918 2026-03-06

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

66 enrolled

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT06784752 2026-03-06

NETTER-3

Phase 3 Recruiting

240 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT02402244 2026-02-27

Project: Every Child for Younger Patients With Cancer

Recruiting

75,000 enrolled

CNSDermatologicEndocrineLymphoidMyeloidNETSarcoma

Carcinoma in Situ, Ganglioneuroma, Lymphoproliferative Disorders, Melanoma, Myeloproliferative Disorders, Neoplasms, Pheochromocytoma, Central Nervous System Neoplasms, Nephroma, Mesoblastic, Desmoid Tumors, Neuroendocrine Tumors

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07314164 2026-02-27

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Recruiting

150 enrolled

Neuroendocrine Tumors

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

740 enrolled

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07429851 2026-02-24

LINEAR

Recruiting

34 enrolled

Neuroendocrine Carcinoma of Lung

NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Phase NA Recruiting

360 enrolled

Cancer Pain, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Stomach Neoplasms, Neuroendocrine Tumors, Visceral Pain

NCT07377487 2026-02-20

INDIGO

Phase NA Recruiting

51 enrolled

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma